Tag: GLP1

  • GLP-1 Drugs Like Ozempic Are Showing a 47 Percent Reduction in Breast Cancer Risk in a Major New Study — and Weight Loss May Not Explain It

    GLP-1 Drugs Like Ozempic Are Showing a 47 Percent Reduction in Breast Cancer Risk in a Major New Study — and Weight Loss May Not Explain It

    The list of conditions that GLP-1 receptor agonists appear to protect against keeps getting longer. These drugs — which include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and the newly approved orforglipron (Foundayo) — were originally developed for type 2 diabetes before emerging as transformative obesity medications. Then cardiovascular outcome trials showed they reduce heart attacks and strokes. Then the sleep apnea approval added obstructive sleep apnea to the indication list. Then studies suggested reductions in kidney disease progression, non-alcoholic fatty liver disease, and alcohol dependence.

    And now, a major study presented at the American Society of Clinical Oncology Annual Meeting in Chicago in early June 2026 and reported widely on June 10, 2026 has added breast cancer to the rapidly expanding list of conditions that GLP-1 drugs appear to protect against — with an effect magnitude that has stunned the oncology community.

    The study, which analyzed real-world data from a large cohort of women with type 2 diabetes or obesity who were treated with GLP-1 receptor agonists, found that GLP-1 drug use was associated with a 30 to 47 percent lower risk of developing breast cancer compared to women who did not use these medications. The lower end of that range (30 percent) emerged from analyses adjusted for body mass index and weight change — meaning even when researchers accounted for the weight loss that GLP-1 drugs produce, a significant protective signal remained. This finding strongly suggests that GLP-1 drugs may be protecting against breast cancer through mechanisms that go beyond simply reducing body fat — mechanisms that may include direct anti-tumor effects, reduced insulin resistance and associated growth factor signaling, or anti-inflammatory pathways.

    Why This Finding Is Biologically Plausible

    The biological connection between metabolic dysfunction, obesity, insulin resistance, and breast cancer risk is well established. Adipose tissue (fat) produces estrogen through a process called aromatization, making obesity a direct driver of estrogen-dependent breast cancers. Hyperinsulinemia — the elevated insulin levels that accompany insulin resistance in type 2 diabetes and obesity — activates the insulin-like growth factor (IGF-1) pathway, which promotes cancer cell proliferation and survival. Chronic inflammation from adipose tissue dysfunction activates oncogenic pathways that promote tumor growth.

    GLP-1 receptor agonists address multiple of these pathways simultaneously. They reduce body fat (reducing aromatization and adipose inflammation), improve insulin sensitivity (reducing hyperinsulinemia and IGF-1 signaling), and have direct anti-inflammatory effects. Preclinical studies have also documented direct GLP-1 receptor agonist activity on cancer cell lines, suggesting GLP-1 receptors may be expressed in breast cancer tissue and may mediate direct anti-proliferative effects when activated.

    The study’s finding that the protective signal persists even after adjustment for weight and BMI is the most provocative result, because it suggests the drug’s biological effects — beyond simple caloric restriction and fat mass reduction — are contributing to cancer protection.

    What This Means for the 15 Million Americans on GLP-1 Drugs

    Approximately 15 million Americans are currently prescribed GLP-1 receptor agonists. The vast majority are taking them for type 2 diabetes or weight management. If the breast cancer protective signal seen in this study is confirmed in larger prospective trials and in controlled analyses, it would represent an additional major health benefit of these medications — one that could influence prescribing decisions, insurance coverage arguments, and cancer prevention discussions.

    The researchers caution that this is observational data from a real-world cohort, not a randomized controlled trial. Confounding variables — the possibility that GLP-1 drug users differ from non-users in ways that independently affect breast cancer risk — must be accounted for before these findings can be considered definitive. Prospective studies and potential randomized trials with cancer outcomes as endpoints are now being planned. The Phase 3 ORCA trial of semaglutide in high-risk cancer prevention populations is one ongoing effort that will provide higher-quality evidence.

    For women currently taking GLP-1 drugs for any indication, this study is not a recommendation to take them as cancer prevention without diabetes or obesity indication — rather, it is an important signal that the health benefits of these medications may be broader than previously understood.

    Frequently Asked Questions

    Q: What did the new GLP-1 and breast cancer study find?

    A: A real-world cohort study presented at ASCO 2026 found that women with type 2 diabetes or obesity who used GLP-1 receptor agonists had a 30–47% lower breast cancer risk compared to non-users. The effect persisted after adjustment for weight loss.

    Q: Does this mean women should take GLP-1 drugs specifically to prevent breast cancer?

    A: No. This is observational data, not a randomized trial. The finding is a promising signal that warrants further research, not a clinical recommendation for GLP-1 drugs as cancer prevention outside of established indications.

    Q: Why might GLP-1 drugs protect against breast cancer beyond weight loss?

    A: By reducing hyperinsulinemia, improving insulin sensitivity (lowering IGF-1 signaling), reducing adipose-tissue inflammation, and potentially through direct GLP-1 receptor activity on breast tissue — all mechanisms independent of weight loss.

    Q: Which GLP-1 drugs were included in the study?

    A: The study analyzed GLP-1 receptor agonist use broadly, including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) among the most commonly used agents. Results were not limited to a specific drug within the class.

    Q: How does this new finding fit with the other cancer data on GLP-1 drugs?

    A: A 2024 Nature Medicine study documented lower incidence of multiple obesity-associated cancers in GLP-1 users. The 2026 ASCO breast cancer study adds specifically to that growing body of evidence suggesting GLP-1 drugs may have broad anti-cancer properties.

    Source link

  • Comparing GLP‑1 Injectable Weight‑Loss Meds, Semaglutide vs Tirzepatide, and Real Side Effects

    Comparing GLP‑1 Injectable Weight‑Loss Meds, Semaglutide vs Tirzepatide, and Real Side Effects

    The debate of Ozempic vs Mounjaro has become one of the most discussed topics in modern weight management. These injectable weight-loss meds, often referred to as GLP‑1 weight-loss drugs, have gained massive attention for their effectiveness in helping people lose significant weight while also improving blood sugar control.

    Both medications were initially developed to treat type 2 diabetes, but clinical results showing dramatic weight reductions sparked their evolution into tools for obesity management.

    While Ozempic and Mounjaro share some similarities, they differ in composition, mechanisms, and potential side effects. Understanding how each drug works and what distinguishes semaglutide vs tirzepatide can help individuals and clinicians make informed choices about treatment options.

    What Are GLP-1 Weight-Loss Drugs?

    GLP-1 receptor agonists are medications that mimic the natural hormone glucagon-like peptide-1 (GLP-1). This hormone helps regulate blood sugar and satiety by slowing down digestion, promoting insulin release, and reducing appetite. When administered as once-weekly injections, these drugs assist patients in feeling full longer and eating less.

    Ozempic (which contains semaglutide) and Mounjaro (which contains tirzepatide) are among the most well-known of this group. Other related drugs include Wegovy and Zepbound, versions approved specifically for weight management rather than diabetes.

    Ozempic vs Mounjaro: Key Differences

    When comparing Ozempic vs Mounjaro, the key difference lies in the drugs’ active ingredients and how they act on the body.

    • Ozempic (semaglutide) targets only the GLP‑1 receptor.
    • Mounjaro (tirzepatide), on the other hand, acts on both the GLP‑1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.

    This dual mechanism allows Mounjaro to potentially offer stronger effects on both insulin control and appetite regulation. Some studies suggest that tirzepatide may lead to greater average weight loss than semaglutide, though long-term outcomes are still being studied.

    Both medications are injectable and typically used once a week. Ozempic has been FDA-approved for type 2 diabetes, while Wegovy (its higher-dose version) is approved for chronic weight management. Similarly, Mounjaro is FDA-approved for diabetes, while its twin drug Zepbound is approved for obesity.

    How Do Ozempic and Mounjaro Help You Lose Weight?

    The success of GLP‑1 weight-loss drugs such as Ozempic and Mounjaro comes down to appetite control and metabolic balance. These medications not only lower blood sugar but also trigger signals that make the body feel full sooner.

    GLP‑1 and GIP hormones play a critical role in sending satiety messages to the brain. By mimicking these hormones, semaglutide and tirzepatide slow gastric emptying (the speed at which food leaves the stomach). As a result, people consume fewer calories without feeling deprived.

    In clinical trials, individuals using semaglutide reported an average weight loss of around 15% of their body weight over 68 weeks, while tirzepatide users experienced reductions as high as 20% in some studies. These results position injectable weight-loss meds like these as some of the most effective non-surgical treatments available today.

    Side Effects of Ozempic and Mounjaro

    As with any medication, both Ozempic and Mounjaro come with potential side effects. For most people, these are temporary and mild, but understanding them helps in managing expectations and safety, according to the World Health Organization.

    Common side effects include:

    • Nausea and vomiting
    • Constipation or diarrhea
    • Bloating or indigestion
    • Mild fatigue or dizziness

    More serious side effects, though less common, can occur. These include pancreatitis, gallbladder inflammation, kidney complications, and in rare cases, thyroid-related tumors. Patients are often monitored for early signs of these conditions, especially if they have a family history of thyroid disease.

    When comparing Ozempic side effects vs Mounjaro side effects, reports suggest that Mounjaro users might experience slightly stronger gastrointestinal symptoms initially, possibly because of its dual-agonist action.

    However, gradual dose adjustments and dietary changes, like eating smaller meals and avoiding greasy foods, can minimize these effects.

    Doctors typically start patients on the lowest dosage to allow the body to adjust. Staying hydrated and taking injections on the same day each week also help reduce discomfort.

    Who Should and Shouldn’t Use Injectable Weight-Loss Meds

    These medications are designed for adults with type 2 diabetes or those classified as overweight or obese (BMI of 30 or higher, or 27 with weight-related conditions). They are not intended for short-term or cosmetic weight loss.

    People with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis, or severe gastrointestinal conditions should avoid GLP‑1 weight-loss drugs unless specifically advised by their physician.

    It’s crucial for potential users to consult their healthcare providers before starting these treatments. A comprehensive health assessment ensures safety and identifies whether related lifestyle changes may be sufficient before turning to medication.

    Cost, Accessibility, and Insurance Coverage

    Access and affordability remain major challenges. Ozempic and Mounjaro can cost anywhere from $900 to $1,300 per month without insurance, and coverage often depends on medical necessity. While insurers frequently cover these drugs for diabetes, weight-loss-only prescriptions may face denials.

    To help offset the price, both drug manufacturers offer savings programs and patient assistance plans. Prices also vary by region and dosage strength, making it worthwhile to consult pharmacies or clinics to find cost-effective options.

    For those comparing Ozempic vs Mounjaro, it’s worth noting that tirzepatide-based drugs (Mounjaro or Zepbound) might have limited availability in some areas due to high demand, as per the Centers for Disease Control and Prevention.

    Ozempic vs Mounjaro: Which One Is Better for You?

    The choice between Ozempic vs Mounjaro depends on a person’s health goals, metabolic profile, and tolerance. Clinical trials show both drugs yield significant weight loss and improved glucose control, but the response varies individually.

    • Those seeking steadier blood sugar control with proven long-term data may prefer Ozempic (semaglutide).
    • Those targeting faster or more substantial fat loss may respond better to Mounjaro (tirzepatide).

    Doctors often base their recommendation on the patient’s overall health, co-existing conditions, and potential side effect management.

    In practice, both options can be effective, success largely depends on consistency, proper dosing, and accompanying lifestyle adjustments such as balanced meals and physical activity.

    Frequently Asked Questions

    1. Can you stop taking Ozempic or Mounjaro once you reach your goal weight?

    Stopping these medications often leads to regained weight because appetite and metabolism return to baseline. Ongoing medical guidance is recommended before tapering off.

    2. Do Ozempic and Mounjaro affect muscle mass as well as fat loss?

    Some users may lose small amounts of lean muscle alongside fat, but maintaining protein intake and resistance exercise helps preserve muscle mass.

    3. Can you drink alcohol while using GLP‑1 weight-loss drugs?

    Light to moderate drinking is generally safe, but alcohol can worsen nausea or affect blood sugar control. It’s best to consult your healthcare provider for limits.

    4. Are there any natural alternatives to GLP‑1 weight-loss drugs?

    Certain lifestyle changes, like high-protein diets, fiber-rich foods, and regular exercise, can naturally boost satiety hormones, though not as powerfully as medical GLP‑1 therapy.



    Source link

  • Uses and Side Effects of Ozempic and Other GLP-1 Weight Loss Drugs

    Uses and Side Effects of Ozempic and Other GLP-1 Weight Loss Drugs

    Ozempic and others in a new class of weight-loss drugs have been called “the medical sensation of the decade.” Are they worthy of all the hype?

    For a deep dive, please see my primer on this topic. OZEMPIC: Risks, Benefits, and Natural Alternatives to GLP-1 Weight-Loss Drugs is available as an ebook, audiobook, and paperback. You can also view my video series for free on the Ozempic topic page or our YouTube channel. Here are some of the key takeaways.

     

    What Is GLP-1?

    A naturally occurring hormone in our body, glucagon-like peptide-1 (GLP-1) plays a role in regulating our blood sugar, appetite, and digestion. Our gastrointestinal tract releases more than 20 different peptide hormones, including GLP-1. The primary stimuli for secreting GLP-1 are meals rich in fats and carbohydrates, and GLP-1’s main action is to signal satiety to the brain. It also slows our digestion. Delaying the rate at which food leaves our stomach not only helps us feel fuller for longer, but also helps with our blood sugar control. When GLP-1 or an agonist (mimic) is dripped into people’s veins, appetite is reduced, leading to markedly reduced food consumption—a decrease in caloric intake by as much as 25 to 50 percent.

     

    About GLP-1 Drugs

    Our GLP-1 hormone acts as an appetite suppressant by targeting parts of the brain responsible for hunger and cravings. GLP-1-secreting cells don’t only line our intestines; they’re also in our brains. These new anti-obesity drugs are GLP-1 agonists, mimicking the hormone’s action by binding to GLP-1 receptors.

    Our body breaks down GLP-1 so quickly that it hardly makes it even one time around our circulatory system, which is why we can’t just take the hormone directly. A compound was discovered—in the venomous saliva of a lizard called the Gila monster—that mimics GLP-1 but is resistant to breakdown. Using that compound as a template, the first GLP-1 agonist was created and approved for the treatment of diabetes about 20 years ago. Instead of most of it being cleared from the body within two and a half minutes, like native, natural GLP-1, much of the drug remains in the body for two and a half hours. That still means twice-daily injections, though, so then came liraglutide, which lasts all day. 

     

    What Is Ozempic?

    Eventually, semaglutide was developed and branded as Ozempic, which could be injected just once a week. Ozempic was approved in 2017 to treat diabetes. Within a few years, a daily oral version had been developed, again for diabetes, but researchers running those clinical trials noticed a surprising side effect: People’s appetites diminished.

     

    How Does Ozempic Work?

    In a way, GLP-1 agonist drugs work like birth control pills. The Pill mimics placental hormones, thereby tricking our body into thinking we’re pregnant all the time. Ozempic-type drugs mimic GLP-1, thereby tricking our body into thinking we’re eating all the time. That’s how it dials down our hunger drive.

     

    Ozempic for Weight Loss

    In the longest trial to date, more than 17,000 individuals were randomized to injections of either high-dose semaglutide or placebo for four years. Overall, those on the drug lost 9 percent more body weight than those in the placebo group, but all the weight was lost in the first 65 weeks. Even though they continued to get injected every week for three more years, they didn’t lose any more weight over the subsequent 143 weeks.

    Weight loss tends to plateau because the same amount of effort to cut calories—whether through willpower, drugs, or surgery—is met with growing resistance as ongoing weight loss increasingly activates our feedback control circuit, stimulating our appetite. In the case of the GLP-1 drugs, the weight loss caused by the initial drop in appetite is undercut by an apparent exponential increase in caloric intake as our body ratchets up our hunger again. Within 12 months, this resistance, combined with the decreased caloric needs from being lighter, matches the persistent effort to cut calories, and weight loss plateaus. And, as soon as we stop taking the drugs, our full appetite resumes and we start regaining the weight we initially lost.

     

    The Cost of Ozempic

    Wegovy, the high-dose Ozempic used for weight loss, costs up to $1,350 a month, which, again, may have to be paid in perpetuity since any lost weight can pile back on if you stop taking it. So, that could cost more than $16,000 a year if paid out-of-pocket for those whose insurance doesn’t cover it.

     

    Ozempic Side Effects

    The most common side effects include nausea, vomiting, diarrhea, and constipation. Gallbladder issues are another side effect; excess cholesterol shed from fat cells can crystalize in our bile like rock candy, forming gallstones.

    Rare but serious adverse effects are also emerging. The package inserts for both semaglutide and tirzepatide list a series of “warnings and precautions” that include thyroid tumors, acute inflammation of the pancreas (pancreatitis), acute gallbladder disease, acute kidney injury (that may stem from dehydration due to excess vomiting or diarrhea), allergic reactions, a heightened risk of bottoming out blood sugars while on blood sugar–lowering medications, worsening eye disease for those with type 2 diabetes, an increase in heart rate requiring monitoring, and suicidal thoughts and behaviors.

     

    What Is “Ozempic Face”?

    “Ozempic face” is a term used to describe a distorted facial appearance among users of the drug. (Similar accounts have been made of “Ozempic butt.”) Media reports have linked the drug with facial aging, but the sagging appearance has been ascribed simply to the accelerated loss of fat in the face. While this interpretation seems logical, a review of the phenomenon concluded that “this explanation cannot fully account for the markedly accelerated facial aging….” Other factors suspected as being responsible for the appearance of premature facial aging include the loss of facial muscle mass, diminished structural integrity of the skin, and changes in stem cell function and hormonal secretion.

     

    Is Ozempic Safe?

    In the first quantitative benefit-versus-harm balance analysis, the researchers concluded that those achieving a 10 percent weight loss had a more than 90 percent chance that the benefits of taking the drugs outweigh the harms, but the opposite was found for individuals achieving only a 5 percent weight loss.

    At this time, we don’t know about the long-term harms or benefits because some of these drugs and dosing schedules are so new. To complicate matters, the American Academy of Pediatrics has suggested offering these drugs for teens and even tweens as young as age 12. These drugs work by acting on the brain, so who knows what effect they might have on childhood development and beyond if young people end up taking them for the rest of their lives. Although we now have evidence of near-term benefit over a few years, we cannot assume long-term safety until it has been demonstrated.

     

    Ozempic Alternatives

    We don’t need to take GLP-1-mimicking drugs. Not only can the ingestion of a plant-based meal more than double GLP-1 secretion, compared to a meat meal, but plant-based diets can also cause weight loss by boosting our resting metabolic rate and incorporating “calorie-trapping” high-fiber foods that flush calories away. The largest study of people eating strictly plant-based found they are about 35 pounds lighter on average.

    When we eat a donut, its fat, sugar, and starch get absorbed quickly, high up, before reaching the part of our digestive tract where we produce most of the hormone that suppresses our appetite, GLP-1. Since the cells that produce GLP-1 in response to calorie exposure are concentrated at the end of our digestive tract, while the majority of the calories we consume are absorbed early on, most calories never make it down far enough. That’s why our appetites aren’t suppressed very much these days. From a GLP-1 standpoint, when we have that donut, it’s like we never ate much of anything. No wonder we reach for donut number two.

    Our prehistoric ancestors are believed to have consumed as much as 100 daily grams of fiber, which is more than six times what most of us are getting these days. We evolved eating massive amounts of whole plant foods—the only places fiber is found in abundance. That enabled out natural satiety mechanisms to keep us from overeating. By eating the way nature intended, we can release GLP-1 the way nature intended. That helps explains why in the medical literature, compared to any other way of eating that didn’t involve portion control, a whole food, plant-based diet has been shown to lead to greater average weight loss than any other diet.

     

    For more in-depth information on Ozempic and GLP-1, check out these resources:



    Source link